Search Results - Therapeutics

47 Results Sort By:
Antifungal Small Peptides
­Described are methods and compositions that provide for the production and use of generating synthetic or recombinant peptides having antifungal properties. UTHealth Ref. No.: 2021-0018 Inventors: Dr. Danielle Garsin and Dr. Michael Lorenz Intellectual Property Status: U.S. provisional patent application filed; Available for licensing Associated...
Published: 10/25/2022   |   Inventor(s): Danielle Garsin, Michael Lorenz
Category(s): Biologics, Therapeutics
LGR4 Specific Monoclonal Antibodies and Their Use
­Researchers at UTHealth have isolated and characterized monoclonal antibodies as well as antibody fragments that specifically binding to LGR4, a 7TM receptor that is highly expressed in major types of solid tumors, including but not limited to colorectal cancer, non-small cell lung cancer, and ovarian cancer. These LGR4 specific monoclonal antibodies...
Published: 6/15/2022   |   Inventor(s): Qingyun (Jim) Liu
Category(s): Biologics, Oncology, Therapeutics, Diagnostics, Research Materials
Mutants and Drug Conjugates of R-Spondin Polypeptides for Cancer Therapy
­R-spondins (RSPOs) are secreted proteins with critical roles in cancer development through binding to LGRs and RNF43/ZNRF3 and potentiating Wnt signaling. Various RSPO mutants were discovered that bind to LGRs but no longer function in Wnt signaling. Fc fusion protein of the RSPO mutants, so called RSPO peptibodies, were conjugated with cytotoxic...
Published: 4/29/2022   |   Inventor(s): Qingyun (Jim) Liu
Category(s): Biologics, Oncology, Therapeutics
Novel Oncolytic Herpes Simplex Virus (oHSV) for Cancer Treatment
­ Researchers from UTHealth have developed a novel oncolytic viral therapy, oHSV-shPKR, which can inhibit tumor cells’ antiviral PKR activity, and increase oncolytic virus infection and replication in both oncolytic viral-resistant and sensitive cancer cells. This novel oHSV-shPKR therapy can significantly increase the anti-tumor immune response...
Published: 1/7/2022   |   Inventor(s): Balveen Kaur, BangXing Hong
Category(s): Biologics, Oncology, Therapeutics
Co-Administration of Oncolytic Herpes Simplex Virus (oHSV) with Cisplatin for Anti-Cancer Immunotherapy
­Researchers from UTHealth and Ohio State University College of Medicine have collaborated to investigate the impact of oHSV therapy in combination with platinum agents using platinum-resistant high-grade serous ovarian carcinoma (HGSOC) as well as platinum-resistant ovarian clear cell carcinoma models. More importantly, they have developed a novel...
Published: 1/7/2022   |   Inventor(s): Balveen Kaur
Category(s): Therapeutics, Oncology
Monoclonal Antibodies Against Oncostatin M Receptor (OSMR) for Therapeutic and Diagnostic Use
­Researchers from UTHealth and The Medical College of Wisconsin have collaborated to reveal the role of OSMR in promoting ovarian cancer cell proliferation and metastasis through activation of STAT3 signaling, as well as illuminated the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment. More particularly, researchers...
Published: 12/16/2021   |   Inventor(s): Zhiqiang An
Category(s): Diagnostics, Therapeutics, Biologics, Oncology
Peptides Targeting Chemotherapy-Resistant Metastatic Cancer Cells for Therapeutic and Diagnostic Use
Researchers at UTHealth have identified new molecules that selectively target metastatic cancer cells in mammals both in vitro and in vivo by screening a combinatorial library in a mouse mammary tumor model of spontaneous metastasis, and demonstrated their application as noninvasive imaging probes and vehicles for cytotoxic therapy delivery in preclinical...
Published: 12/16/2021   |   Inventor(s): Mikhail Kolonin
Category(s): Oncology, Therapeutics, Diagnostics
Monoclonal Antibodies Against Chitinase 3-like-1 (Chi3l1) for Therapeutic and Diagnostic Use
­Researchers at UTHealth have unveiled a critical role of Chi3l1 in hepatic platelet recruitment during acetaminophen (APAP)-induced liver injury (AILI) using murine models of AILI and concanavalin A (Con A)-induced hepatitis. Significantly, they have developed anti-Chi3l1 monoclonal antibodies and demonstrated the feasibility of targeting CHI3L1...
Published: 12/6/2021   |   Inventor(s): Zhiqiang An, Changqing (Cynthia) Ju
Category(s): Biologics, Therapeutics, Oncology
Novel Channelrhodopsins for Optogenetics Gene Therapy
When expressed in targeted neurons, light-sensitive channelrhodopsin proteins (ChRs) have the ability to selectively manipulate neuronal activity in a light-dependent manner. Gene therapy using anion ChRs (ACRs) has the potential for treating excessive neuron firing in conditions such as Parkinson’s disease, neuropathic pain and epilepsy, while...
Published: 6/2/2021   |   Inventor(s): John Spudich, Elena G Govorunova, Oleg A Sineshchekov
Category(s): Therapeutics, Research Materials
Novel Fendiline Derivatives for the Treatment of KRAS Mutant Tumors
Novel Compounds and Methods of Use for the Treatment and Prevention of Cancer via Inhibition of the K-Ras Pathway Background: The Ras protein family members belong to a class of proteins called small GTPases and when activated by incoming signals, it subsequently switches on other genes involved in cell growth, differentiation, and survival. As a...
Published: 9/22/2020   |   Inventor(s):  
Category(s): Oncology, Therapeutics
1 2 3 4 5 
© 2022. All Rights Reserved. Powered by Inteum